Table 3.
Lead-in period | Zespri® SunGold kiwifruit | Metamucil® | |||||
---|---|---|---|---|---|---|---|
Parameter | Mean | sd | Mean | sd | Mean | sd | P |
No. of bowel movements/week | 7·2 | 3·5 | 9·1* | 4·9 | 8·1 | 3·8 | 0·02 |
No. of CBM/week | 4·2 | 3·1 | 6·9* | 4·3 | 5·5 | 4·2 | 0·002 |
No. of SBM/week | 6·7 | 3·6 | 8·6 | 5·0 | 7·2 | 4·5 | 0·226 |
Number of strained bowel movements/week | 3·7 | 2·6 | 1·7* | 2·4 | 2·5* | 3·4 | <0·001 |
Average Bristol Stool Scale score | 3·24 | 1·13 | 4·15*† | 1·26 | 3·52 | 1·27 | <0·001 |
Proportion of bowel movements using laxatives (%) | 2·8 | 10·9 | 5·2 | 20·9 | 3·4 | 17·7 | ‡ |
CBM, complete bowel movements; SBM, spontaneous bowel movements.
Mean value was significantly different from that for the lead-in period, based on least significant difference.
Mean value was significantly different from that for Metamucil®, based on least significant difference (P = 0·025).
Not analysed. Of the participants, 92 % did not use.